A Phase 2 interventional study of SHR 1210+apatinib in Hepatocellular Carcinoma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing camrelizumab in Carcinoma, Hepatocellular — 19 open to participants now, 24 under way, 8 of them phase 3. camrelizumab · Carcinoma, Hepatocellular.
Among the 44 studies testing camrelizumab in Carcinoma, Hepatocellular, this one is the 10th largest by enrollment, is one of 2 that started in 2018, is one of 24 in phase 2, and was the 3rd registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →19 of the 44 studies testing camrelizumab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Guohui Xu · Sites in China
Ages 18–80
Sun Yat-sen University · Sites in China
Ages 18–75
Wen Tianfu · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 33 · Phase 3 9
First in 2016; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 51 across the 44 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 44 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd.: 5 open now, 7 under way, 4 of them phase 3. Of 5 finished, 3 (60%) have results posted.
Among the 13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd., this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 2, and was the 3rd registered.
Jiangsu HengRui Medicine Co., Ltd.’s Carcinoma, Hepatocellular studies by the year they started, since 2014.
5 of the studies testing camrelizumab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05062837Phase 3Guangxi Medical UniversityHepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | 2026-12-30 |
| NCT05738616Phase 3Wen TianfuLenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) | 2027-05-01 |
| NCT07618546Henan Cancer HospitalA Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors | 2027-03-31 |
| NCT06360042Peking University Cancer Hospital & InstituteAnti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | 2027-03-31 |
| NCT07100392Fudan UniversityTauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies testing camrelizumab in Carcinoma, Hepatocellular, from their registry updates:
Among Jiangsu HengRui Medicine Co., Ltd.’s 13 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.
SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor (TKI).
Patients with advanced HCC who failed or intolerable to sorafenib will receive apatinib 250mg orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks. The efficacy and safety will be observed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks.
Drug: SHR 1210+apatinib
Drug pages: Camrelizumab · Apatinib
SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
Objective Response Rate (ORR)
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
Time frame: Up to approximately 12 months
Duration of Response (DoR)
Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
Time frame: Up to approximately 12 months
Disease Control Rate (DCR)
Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
Time frame: Up to approximately 12 months
Time to Objective Response(TTR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
Time to objective response,TTR
Time frame: Up to approximately 12 months
9-month Survival Rate
9-month survival rate
Time frame: Up to approximately 9 months
12-month Survival Rate
12-month survival rate
Time frame: Up to approximately 12 months
Overall Survival(OS)
Overall survival(OS)
Time frame: Up to approximately 36 months
Progression-free Survival(PFS)
Progression-free survival(PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
Time frame: Up to approximately 12 months
| Milestone | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment |
|---|---|---|
| Started | 120 | 70 |
| Completed | 16 | 8 |
| Not completed | 104 | 62 |
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
| Percentage of participants | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment |
|---|---|---|
| Objective Response Rate (ORR) | 22.5 (15.4 to 31.0) | 34.3 (23.3 to 46.6) |
Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
| Months | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment |
|---|---|---|
| Duration of Response (DoR) | NA (NA to NA) | 14.8 (5.5 to NA) |
Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
| Percentage of participants | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment |
|---|---|---|
| Disease Control Rate (DCR) | 75.8 (67.2 to 83.2) | 78.6 (67.1 to 87.5) |
Time to objective response,TTR
| Months | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment |
|---|---|---|
| Time to Objective Response(TTR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). | 1.87 (1.81 to 3.68) | 1.87 (1.84 to 3.70) |
9-month survival rate
| Percentage of participants | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment |
|---|---|---|
| 9-month Survival Rate | 79.1 (70.7 to 85.4) | 86.7 (76.0 to 92.8) |
12-month survival rate
| Percentage of participants | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment |
|---|---|---|
| 12-month Survival Rate | 68.2 (59.0 to 75.7) | 74.7 (62.5 to 83.5) |
Overall survival(OS)
| Months | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment |
|---|---|---|
| Overall Survival(OS) | 21.8 (17.3 to 25.6) | 20.1 (14.9 to NA) |
Progression-free survival(PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
| Months | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment |
|---|---|---|
| Progression-free Survival(PFS) | 5.5 (3.7 to 5.6) | 5.7 (5.4 to 7.4) |
Collected over 36 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SHR 1210+Apatinib | 118/190 (62.1%) | 92/190 (48.4%) | 189/190 (99.5%) |
| Event | SHR 1210+Apatinib |
|---|---|
| Hepatic enzyme abnormalInvestigations | 15/190 |
| Disease progressionGeneral disorders | 13/190 |
| Hepatic function abnormalHepatobiliary disorders | 7/190 |
| PyrexiaGeneral disorders | 5/190 |
| Multiple organ dysfunction syndromeGeneral disorders | 4/190 |
| PneumoniaInfections and infestations | 4/190 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/190 |
| Reactive capillary endothelial proliferationImmune system disorders | 4/190 |
| Sudden cardiac deathGeneral disorders | 3/190 |
| Alanine aminotransferase increasedInvestigations | 3/190 |
| Event | SHR 1210+Apatinib |
|---|---|
| Aspartate aminotransferase increasedInvestigations | 138/190 |
| Platelet count decreasedInvestigations | 125/190 |
| Alanine aminotransferase increasedInvestigations | 116/190 |
| ProteinuriaRenal and urinary disorders | 112/190 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 108/190 |
| White blood cell count decreasedInvestigations | 107/190 |
| Blood bilirubin increasedInvestigations | 98/190 |
| HypertensionVascular disorders | 95/190 |
| Neutrophil count decreasedInvestigations | 89/190 |
| AstheniaGeneral disorders | 76/190 |
| Age, Continuous(years) | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment | Total |
|---|---|---|---|
| Mean | 50.7 ± 11 | 51.9 ± 11.28 | 51.1 ± 11.09 |
| Sex: Female, Male(Participants) | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment | Total |
|---|---|---|---|
| Female | 14 | 7 | 21 |
| Male | 106 | 63 | 169 |
| Race and Ethnicity Not Collected(Participants) | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Group Having Received First-Line Systemic Treatment | Group Not Having Received First-Line Systemic Treatment | Total |
|---|---|---|---|
| China | 120 | 70 | 190 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Mar 2021, 36 months.
Results were first posted in Feb 2026, 4 years 11 months after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 36 months is close to that.
Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Camrelizumab · Apatinib
Jiangsu HengRui Medicine Co., Ltd. →